climbs another 20% today after yesterday’s meteoric rise following their FDAS approval fo their skin wound gel. Given the broad application of the product (Dermacyn, Microcyn, and various formulations are used around the world for everything from diabetic foot ulcer healing to surgical theater sterilization) we are wondering how long it will be until a big wound management player, such as Johnson&Johnson (NYSE: JNJ) or Smith&Nephew (NYSE: SNN), scoops them up...
to read more check out:
http://myshareholder.com/blog.html